Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin

Head & Neck ◽  
2002 ◽  
Vol 24 (7) ◽  
pp. 632-636 ◽  
Author(s):  
Marilena Vered ◽  
Efraim Braunstein ◽  
Amos Buchner
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Salivary Gland ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adenoid Cystic Carcinoma ◽  
Immunohistochemical Study ◽  
Growth Factor Receptor ◽  
Adenoid Cystic ◽  
Epidermal Growth

Primary adenoid cystic carcinoma of the liver: A case report

2017 ◽  
Vol 2 (1) ◽  
pp. 20
Author(s):  
Padmaj S. Kulkarni ◽  
Girish Phadke ◽  
Mahesh M. Mandolkar ◽  
Sujit Nilegaonkar ◽  
Sonali Deshmukh
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Case Report ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adenoid Cystic Carcinoma ◽  
Rare Case ◽  
Growth Factor Receptor ◽  
Adenoid Cystic ◽  
Epidermal Growth

<p><span>Adenoid cystic carcinoma (ACC) is primarily found in the salivary glands and rarely at other organs but never reported as liver primary. This is a very rare case of primary ACC of the liver which was not resectable and managed with chemotherapy and targeted therapy. The patient progressed on imatinib (c-kit positive) while responded to chemotherapy and gefitinib (epidermal growth factor receptor mutation absent).</span></p>

scholarly journals Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

2007 ◽  
Vol 25 (25) ◽  
pp. 3978-3984 ◽  
Author(s):  
Mark Agulnik ◽  
Ezra W.E. Cohen ◽  
Roger B. Cohen ◽  
Eric X. Chen ◽  
Everett E. Vokes ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adenoid Cystic Carcinoma ◽  
Phase Ii ◽  
Progressive Disease ◽  
Phase Ii Study ◽  
Growth Factor Receptor ◽  
Adenoid Cystic ◽  
Epidermal Growth

PurposeExpression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic aggressiveness and poor prognosis in malignant salivary gland tumors (MSGTs). This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs.Patients and MethodsPatients with progressive, recurrent, or metastatic adenoid cystic carcinoma (ACC) immunohistochemically expressing at least 1+ EGFR and/or 2+ erbB2 were treated with lapatinib 1,500 mg daily, in a two-stage cohort. Patients with non-ACC MSGTs were treated as a separate single-stage cohort.ResultsOf 62 patients screened, 29 of 33 (88%) ACC and 28 of 29 (97%) non-ACC patients expressed EGFR and/or erbB2. Forty patients with progressive disease were enrolled onto the study. Among 19 assessable ACC patients, there were no objective responses, 15 patients (79%) had stable disease (SD), nine patients (47%) had SD ≥ 6 months, and four patients (21%) had progressive disease (PD). For 17 assessable non-ACC patients, there were no objective responses, eight patients (47%) had SD, four patients (24%) had SD ≥ 6 months, and nine patients (53%) had PD. The most frequent adverse events were grade 1 to 2 diarrhea, fatigue, and rash. Eight paired tumor biopsies for correlative studies were procured; results did not correlate with clinical outcome.ConclusionAlthough no responses were observed, lapatinib was well tolerated, with prolonged tumor stabilization of ≥ 6 months in 36% (95% CI, 21% to 54%) of assessable patients. The antitumor effects of lapatinib in MGSTs appear mainly cytostatic, hence evaluation of other molecular targeted agents, or combinations with lapatinib, may be considered. Continued efforts should be made to gain better understanding into the biology of this heterogeneous group of malignancies.

Sign in / Sign up

Export Citation Format

Share Document